Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
Abstract
Introduction The goal of organ dysfunction Phase I trials is to characterize the safety and pharmacokinetics of novel agents in cancer patients with liver or kidney dysfunction, but the clinical benefit is not well established. Methods We reviewed 170 patients across 15 liver dysfunction studies at our institution, grouped based on the NCI-Organ Dysfunction Working Group criteria or Child-Pugh Score. Results The median survival for the entire...
Paper Details
Title
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
Published Date
Jan 19, 2017
Journal
Volume
35
Issue
3
Pages
386 - 391
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History